NCT07775456 Calcium Phosphate Periapical Periodontitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07775456 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 1 September 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07775456 is a hot trial to watch
Periapical Periodontitis is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07775456 is notable because it evaluates Calcium Phosphate in a Phase 2 design sponsored by Future University in Egypt. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07775456 |
| Official title | Evaluation of Postoperative Pain and Bacterial Load After Hyalone or Calcium Hydroxide Medication in Mandibular First Molars (HYACAL-ENDO) |
| Phase / status | Phase 2 / Active, not recruiting |
| Intervention | Calcium Phosphate |
| Sponsor | Future University in Egypt |
| Geography | Egypt |
| Enrollment | 28 |
| Primary endpoint | Bacterial load reductiion |
| Endpoint time frame | 1 week |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
This randomized controlled clinical trial aims to evaluate the effect of Hyalone hydrogel compared with calcium hydroxide as an intracanal medicament on postoperative pain and bacterial load reduction in mandibular first molars with necrotic pulp and symptomatic apical periodontitis. The rationale for the study is based on the important role of intracanal medicaments in reducing residual microorganisms between treatment appointments. Calcium hydroxide is widely used because of its antimicrobial activity and alkaline pH; however, it has limitations related to its distribution, adherence to canal walls, antimicrobial spectrum, and effectiveness against microorganisms in complex root canal anatomy. Hyaluronic acid hydrogel has demonstrated potential benefits in dentistry, including supporting tissue healing and reducing inflammation and pain, and may therefore represent a promising alternative intracanal medicament. The study will include
Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 28 participants across Egypt shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Bacterial load reductiion (1 week) — Antimicrobial effect will be measured by counting the number of bacteria present in the root canal using serial dilution technique. Samples will be acquired by placing #15 sterile paper points in the canal for 1 minute each. Some of the paper points will be placed in broth to isolate the facultative anaerobes, while the others will be placed in a suitable transport medium to isolate the obligate anaerobes. The tubes
- postoperative pain measurement (1 week) — Postoperative pain will be measured using numerical rate scale (NRS) after 6, 12, 24, 48, 72 and 1 week from the end of endodontic treatment. The NRS consists of 11 point scale from 0 to 10 anchored by two extremes "No pain" and "pain as bad as could be", patient will be asked to choose the mark that represent their level of pain. Pain level will be assigned to one of 4 categorical scores: None (0); Mild (1-3); Moder
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Calcium Phosphate is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Future University in Egypt is resolved to a normalized organization record in Egypt. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07775456 provides a focused lens on Periapical Periodontitis development. Its value will be determined by whether Calcium Phosphate can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
